Peptide LibraryKisspeptin-54 (Metastin) dosage in published studies and labels
These are the doses used for Kisspeptin-54 (Metastin) in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Kisspeptin-54 has published human dosing from academic endocrine research: subcutaneous infusion at 0.1, 0.3 or 1.0 nmol/kg/h over 8 hours in healthy women, stimulating gonadotrophin release. That dosing is a weight-based infusion rate delivered in a research setting, not a self-administered regimen, and no product containing it is approved.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.1-1.0 nmol/kg/h by subcutaneous infusion |
| Route | Subcutaneous infusion · Intravenous |
| Frequency | Continuous infusion over 8 hours in the published study |
| Duration studied | Acute, single-session protocols |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Subcutaneous infusion study in healthy women (2016)Clinical trial · Human endocrine physiology study | Healthy women (n=4), early follicular phase across 4 separate menstrual cycles | 0.1, 0.3 or 1.0 nmol/kg/h, or saline | Subcutaneous infusion | Continuous over 8 hours | 8-hour infusion per cycle | Luteinising hormone and gonadotrophin release, and its relationship to baseline oestradiol | Subcutaneous infusion of kisspeptin-54 stimulates gonadotrophin release in women. Clin Endocrinol (Oxf). 2016. |
| Reproductive hormone and anxiety study (2025)Clinical trial · Human physiology study | Human participants | Per study protocol | Intravenous | — | — | Reproductive hormones and anxiety measures | Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans. J Clin Endocrinol Metab. 2025. |
Where sources disagree
- Published dosing is an infusion rate in nanomoles per kilogram per hour, sustained over 8 hours under supervision. Kisspeptin sold for self-injection is dosed as a fixed bolus in micrograms; the two are not interchangeable, and a rate cannot be converted into a bolus without changing what was studied.
- Kisspeptin-54 and kisspeptin-10 are different lengths of the same parent peptide, and studies are indexed under kisspeptin, KP-54, KP-10, metastin and kisspeptin-112-121. Evidence for one length is not automatically evidence for the other.
- All published human work is acute and mechanistic, measuring a hormone response over hours. Nothing establishes a repeated-dosing regimen or its safety over time.